Rate My Professor Patrick Manning

Manning's research focuses on endocrinology and diabetes, including clinical trials in metabolism, the link between obesity and insulin resistance, effects of meal composition on postprandial inflammation, and interventions for type 2 diabetes and osteoporosis. He has contributed to international multicenter trials such as the FIELD study on fenofibrate effects in type 2 diabetes (The Lancet, 2005), TECOS on sitagliptin cardiovascular outcomes (New England Journal of Medicine, 2015), Irbesartan in diabetic nephropathy (2001), and Camellia-TIMI on lorcaserin in obesity. Recent publications include 'Machine learning-based identification of abnormal functional connectivity in obesity across different metabolic states' (Communications Medicine, 2026), 'A pituitary macroadenoma cosecreting prolactin and growth hormone' (JCEM Case Reports, 2025), and 'Variational autoencoder learns better feature representations for EEG-based obesity classification' (2025). As principal or joint investigator, he has obtained grants totaling over $1.9 million. Manning has supervised PhD and postgraduate students, served as President of the New Zealand Society for the Study of Diabetes (2006-2009), Chairperson of the Royal Australasian College of Physicians Specialist Training Committee for Endocrinology (New Zealand, 2017-present), and held roles on Health Research Council committees including the Biomedical Research Committee and College of Experts.